413599-62-9
413599-62-9 性质
| 储存条件 | Store at -20°C |
|---|---|
| 溶解度 | DMSO：20.83 mg/mL (45.35 mM)；水：< 0.1 mg/mL（不溶） |
| 形态 | 固体 |
| 颜色 | 白色至米白色 |
413599-62-9 用途与合成方法
| Target | Value |
|
KDR
() | |
|
Flt-1
() |
ZD4190 exhibits cytotoxic activity against the tumor cells.
ZD4190 (100 mg/kg, p.o.) effectively delays MDA-MB-435 tumor growth in mice. In ZD4190-treated tumors, 18F-FPPRGD2 uptake has decreased significantly relative to baseline by 26.74±8.12% (p<0.05) on day 1 and by 41.19±6.63% (p<0.01) on day 3, then has returned to baseline on day 7. Tumor uptake of 18F-FLT has also decreased on both day 1 and day 3 after initiation of ZD4190 treatment. However, ZD4190 does not significantly change 18F-FDG uptake in tumors, compared with the control group. ZD4190 (50 mg/kg, p.o.) prevents outgrowth of residual tumour in a muscle model of minimal residual carcinoma. ZD4190 (12.5-100 mg/kg, p.o.) produces a dose-dependent reduction in K(trans) in PC-3 prostate tumors. At 100 mg/kg, ZD4190 reduces K(trans) in PC-3 tumors by 31% following 2 doses and by 53% following 8 doses.
413599-62-9 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2026-07-06 | S6543 | 413599-62-9 | 413599-62-9 | 2mg | 1614.2 |
| 2026-06-05 | HY-U00002 | 413599-62-9 | 1 mg | 516 |
